Single-Dose Oritavancin Versus 7–10 Days of Vancomycin in the Treatment of Gram-Positive Acute Bacterial Skin and Skin Structure Infections: The SOLO II Noninferiority Study | Zendy

G. Ralph Corey | Zendy; Samantha Good | Zendy; Hai Jiang | Zendy; Greg Moeck | Zendy; Matthew A. Wikler | Zendy; Sinikka Green | Zendy; Paul S. Manos | Zendy; Richard Keech | Zendy; Rajesh Singh | Zendy; Barry Heller | Zendy; N. I. Bubnova | Zendy; William O’Riordan | Zendy

Open Access

Single-Dose Oritavancin Versus 7–10 Days of Vancomycin in the Treatment of Gram-Positive Acute Bacterial Skin and Skin Structure Infections: The SOLO II Noninferiority Study

Author(s) -

G. Ralph Corey,

Samantha Good,

Hai Jiang,

Greg Moeck,

Matthew A. Wikler,

Sinikka Green,

Paul S. Manos,

Richard Keech,

Rajesh Singh,

Barry Heller,

N. I. Bubnova,

William O’Riordan

Publication year - 2014

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciu778

Subject(s) - medicine , vancomycin , clinical endpoint , antibiotics , methicillin resistant staphylococcus aureus , adverse effect , surgery , staphylococcus aureus , randomized controlled trial , skin infection , population , confidence interval , gastroenterology , microbiology and biotechnology , environmental health , biology , bacteria , genetics

Oritavancin is a lipoglycopeptide antibiotic with rapid bactericidal activity against gram-positive bacteria. Its concentration-dependent activity and long half-life allow for single-dose treatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research